Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 50, Issue 1, 2005, Pages 51-58

  Laack, Eckart ^a   Scheffler, Antje ^a   Burkholder, Iris ^b   Boeters, Ina ^a   Andritzky, Birte ^a   Schuch, Gunter ^a   Görn, Michael ^a   Vohwinkel, Gaby ^a   Edler, Lutz ^b   Fiedler, Walter ^a   Hossfeld, Dieter Kurt ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenic factors; MMP 9; NSCLC; Prognostic factors; VEGF

Indexed keywords

GELATINASE B; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24744466501     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.05.011     Document Type: Article

References (29)

1. D.M. Parkin The global burden of cancer Semin Cancer Biol 8 1998 219 235
2. F. Clifton, and C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1711 1717
3. D.M. Finkelstein, D.S. Ettinger, and J.C. Ruckdeschel Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group J Clin Oncol 4 1986 702 709
4. J.P. O'Connell, M.G. Kris, R.J. Gralla, S. Groshen, A. Trust, and J.J. Fiore Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy J Clin Oncol 4 1986 1604 1614
5. J. Folkman, K. Watson, D. Ingbher, and D. Hanahan Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339 1989 58 59
6. J. Folkman What is the evidence that tumours are angiogenesis-dependent? J Natl Cancer Inst 82 1991 4 6
7. L. Holmgren, M.S. O'Reilly, and J. Folkman Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1 1985 149 153
8. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis Cell 86 1996 353 364
9. A.L. Harris Antiangiogenesis for cancer therapy Lancet 349 1997 13 15
10. J. Lei, A. Jiang, and D. Pei Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF 183 Biochim Biophys Acta 1443 1998 400 406
11. B. Millauer, S. Wizigmann-Voss, H. Schnurch, R. Martinez, N.P. Moller, and W. Risau High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis Cell 72 1993 835 846
12. C. de Vries, J.A. Escobebo, H. Ueno, K. Houck, N. Ferrara, and L.T. Williams The fms-like tyrosine kinase, a receptor of vascular endothelial growth factor Science 255 1992 989 991
13. Y. Takahashi, Y. Kitadai, C.D. Bucana, K.R. Cleary, and L.M. Ellis Expression of vascular endothelial growth factor and its receptor: KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer Cancer Res 55 1995 3964 3968
14. H. Kimura, K. Konsihi, T. Nukui, M. Kaji, K. Maeda, and K. Yabushita Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma J Surg Oncol 76 2001 31 36
15. J. Mattern, R. Koomagi, and M. Volm Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas Int J Oncol 6 1995 1059 1062
16. D.E. Kleiner, and W.G. Stetler-Stevenson Matrix metalloproteinases and metastasis Cancer Chemother Pharmacol 43 1999 42 51
17. T.M. Gress, F. Muller-Pilasch, M.M. Lerch, H. Friess, M. Buchler, and G. Adler Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer Int J Cancer 62 1995 407 413
18. H. Iwata, S. Kobayashi, H. Iwase, A. Masaoka, N. Fujimoto, and Y. Okada Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas Jpn J Cancer Res 87 1996 602 611
19. E. Laack, N. Dickgreber, T. Müller, A. Knuth, J. Benk, and C. Lorenz Randomized phase III study of gemcitabine and vinorelbine (GV) versus gemcitabine, vinorelbine and cisplatin (GVP) in the treatment of advanced non-small cell lung cancer (NSCLC) J Clin Oncol 22 2004 2348 2356
20. E. Laack, A. Köhler, C. Kugler, J. Dierlamm, C. Knuffmann, and G. Vohwinkel Pretreatment matrix metalloproteinase-9 and vascular endothelial growth factor serum levels in non-small cell lung cancer Ann Oncol 13 2002 1550 1557
21. M. Smylie, R. Mercier, D. Aboulafia, R. Tucker, P. Bonomi, and M. Collier Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 20 2001 307 [abstract]
22. D. Bissett, K.J. O'Byrne, J. von Pawel, U. Gatzemeier, A. Price, and M. Nicolson Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 21 2002 296
23. V. Gregorc, V. Ludovini, L. Pistola, S. Darwish, M. Ragusa, and L. Di Carlo Influence of vascular endothelial growth factor (VEGF) and haemoglobin (Hb) on survival of non-small cell lung cancer patients (NSCLC) Ann Oncol 13 2002 131 [abstract]
24. N. Takigawa, Y. Segawa, N. Fujimoto, K. Hotta, and K. Eguchi Elevated vascular endothelial growth factor in sera of patients with lung cancer Anticancer Res 18 1998 1251 1254
25. J.H. Choi, H.C. Kim, H.Y. Lim, D.K. Nam, H.S. Kim, and J.W. Yi Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts Lung Cancer 33 2001 171 179
26. D. Brattstrom, M. Bergqvist, A. Larsson, J. Holmertz, P. Hesselius, and L. Rosenberg Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients Anticancer Res 18 1998 1123 1127
27. D. Brattstrom, M. Bergqvist, P. Hesselius, A. Larsson, K. Lamberg, and J. Wernlund Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients Lung Cancer 37 2002 57 63
28. D. Brattstrom, M. Bergqvist, P. Hesselius, A. Larsson, G. Wagenius, and O. Brodin Serum VEGF and bFGF prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer Lung Cancer 43 2004 55 62
29. P. Lissoni, F. Rovelli, F. Malugani, F. Brivio, L. Fumagalli, and G.S. Gardani Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer Int J Biol Markers 18 2003 152 155